All News

October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.

Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.

Black and Hispanic women had higher rates of hormone therapy discontinuation in a new study. Intira Sriprasert, MD, PhD, discusses barriers and primary care interventions.

Cheryl Cox Kinney, MD, identifies VMS red flags that warrant further evaluation, including fever, weight loss, lymphadenopathy, and persistent symptoms.

Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.

TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.

TMS 2026: Approximately 21% of women initiated systemic HT after menopause, with substantial declines in treatment persistence during the first 2 years.

TMS 2026: JoAnn Pinkerton, MD, discusses elinzanetant's onset of VMS relief, common adverse effects, and treatment expectations for primary care physicians.

Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.

An EHR-integrated tool matched manual CKD and cardiovascular risk assessments in 60 patients and showed promise for improving risk-based kidney care in primary care.

TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.

TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.

TMS 2026: Stephanie Faubion, MD, on how to identify overlooked menopause symptoms and guide hormonal or nonhormonal treatment decisions in primary care settings.

TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.

JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.

TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.

TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.

TMS 2026: Pauline Maki, PhD, discusses real-world OPTION-VMS data linking fezolinetant to improvements in menopausal VMS, depression, and anxiety symptoms.